Mounjaro vs Ozempic: A 2026 Head-to-Head Comparison Backed by Clinical Trial Data

(Note: "Manjaro" is a common misspelling of Mounjaro. Eli Lilly's brand is Mounjaro.)

Key Takeaways

• Mounjaro contains tirzepatide; Ozempic contains semaglutide. They are different molecules with different mechanisms.
• In SURPASS-2, the only direct head-to-head trial, tirzepatide produced larger A1C reductions and more weight loss than semaglutide 1 mg across all three tirzepatide doses (Frias et al., NEJM 2021).
• Both drugs are FDA-approved only for type 2 diabetes. Weight-loss approvals are Zepbound (tirzepatide) and Wegovy (semaglutide).
• Side-effect profiles are similar (nausea, vomiting, diarrhea, constipation), with slightly higher GI rates for tirzepatide at top doses.
• Cash prices are within a few hundred dollars per month. Insurance coverage varies more than list price does.

Direct answer (40-60 words)

Mounjaro is tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic is semaglutide, a GLP-1 only agonist. In the head-to-head SURPASS-2 trial, tirzepatide produced a larger A1C reduction (-2.30% vs -1.86% at top doses) and 5.5 kg more weight loss than semaglutide 1 mg over 40 weeks.

Table of contents

1. The 30-second answer
2. Active ingredients and mechanisms
3. FDA-approved uses
4. Mounjaro vs Ozempic comparison table
5. SURPASS-2: the head-to-head trial
6. Weight-loss data outside diabetes
7. Side effects compared
8. Dosing and titration
9. Pen devices and how to inject each
10. Cost and insurance coverage
11. Switching between Mounjaro and Ozempic
12. Which is better for me?
13. FAQ

Active ingredients and mechanisms

The first thing to know about Mounjaro vs Ozempic is that they are not different brands of the same drug. They contain different active ingredients.

Mounjaro contains tirzepatide, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. Eli Lilly developed and manufactures it.

Ozempic contains semaglutide, a 31-amino-acid synthetic peptide that activates only the GLP-1 receptor. Novo Nordisk developed and manufactures it.

GLP-1 receptor activation slows gastric emptying, increases insulin secretion, suppresses glucagon, and reduces appetite. GIP receptor activation, when added on top, contributes additional insulin secretion at high glucose, improves lipid handling, and may further enhance satiety (Samms et al., Trends Endocrinol Metab 2020).

The dual mechanism of tirzepatide is the reason head-to-head trial data favors Mounjaro on weight and A1C endpoints. It is hitting two levers at once instead of one.

FDA-approved uses

Both drugs are FDA-approved only for type 2 diabetes management. Neither is FDA-approved for weight loss under its diabetes brand name.

• Mounjaro: approved May 2022 for type 2 diabetes
• Ozempic: approved December 2017 for type 2 diabetes; cardiovascular risk-reduction indication added in 2020

The same molecules are approved for chronic weight management under different brand names:

• Zepbound (tirzepatide): approved November 2023 for chronic weight management
• Wegovy (semaglutide): approved June 2021 for chronic weight management; cardiovascular risk-reduction in obesity added in 2024

So a prescription for Mounjaro is a diabetes prescription. A prescription for Ozempic is a diabetes prescription. Off-label use of either for weight loss is legal but is often denied by insurance.

Mounjaro vs Ozempic comparison table

Feature	Mounjaro	Ozempic
Active ingredient	Tirzepatide	Semaglutide
Receptor	GLP-1 + GIP (dual)	GLP-1 only
Manufacturer	Eli Lilly	Novo Nordisk
FDA approval year	2022	2017
FDA-approved use	Type 2 diabetes	Type 2 diabetes; CV risk reduction
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg/wk	0.25, 0.5, 1, 2 mg/wk
Half-life	~5 days	~7 days
Pen type	Single-dose, prefilled	Multi-dose, dial-a-dose
A1C reduction at top dose (head-to-head)	-2.30% (15 mg)	-1.86% (1 mg)
Weight loss at top dose (head-to-head)	-11.2 kg (15 mg)	-5.7 kg (1 mg)
Cash price (Q1 2026)	$1,000 to $1,250/mo	$940 to $1,150/mo
Manufacturer savings card	Yes (commercial only)	Yes (commercial only)

SURPASS-2: the head-to-head trial

The only direct trial comparing the two molecules was SURPASS-2 (Frias et al., NEJM 2021). 1,879 adults with type 2 diabetes on metformin were randomized to tirzepatide 5, 10, or 15 mg weekly, or to semaglutide 1 mg weekly, for 40 weeks.

Outcomes at week 40:

Outcome	Tirzepatide 5 mg	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 1 mg
A1C change	-2.01%	-2.24%	-2.30%	-1.86%
Weight change	-7.6 kg	-9.3 kg	-11.2 kg	-5.7 kg
Reached A1C <7%	82%	86%	86%	79%
Reached A1C <5.7%	27%	40%	46%	19%
Discontinuation due to AE	6.0%	8.4%	8.5%	4.1%

Tirzepatide produced larger A1C drops and more weight loss at every dose. Discontinuation due to side effects was modestly higher for tirzepatide at higher doses.

Important caveats. SURPASS-2 used semaglutide 1 mg, not 2 mg (the highest dose available now). A 2 mg vs 15 mg head-to-head has not been published. Cross-trial comparisons between SUSTAIN-FORTE (semaglutide 2 mg, A1C -2.1%) and SURPASS-2 suggest tirzepatide 15 mg still edges out semaglutide 2 mg, but the comparison is not direct.

Weight-loss data outside diabetes

For non-diabetic patients with obesity, the relevant trials are SURMOUNT-1 (tirzepatide as Zepbound) and STEP 1 (semaglutide as Wegovy). The two drugs are sold under different brand names for weight loss, but the molecule comparison still tells us what to expect.

Trial	Population	Duration	Top dose result	Placebo result
SURMOUNT-1	Obesity, no T2D, N=2,539	72 wks	-20.9% body weight (15 mg)	-3.1%
STEP 1	Obesity, no T2D, N=1,961	68 wks	-14.9% body weight (2.4 mg semaglutide)	-2.4%

Tirzepatide produced about 6 percentage points more average weight loss. For someone starting at 200 pounds, that is roughly an additional 12 pounds.

This pattern matters even when comparing the diabetes-indication versions (Mounjaro vs Ozempic), because the weight-loss difference is a property of the molecules, not the brand names. Patients who use Mounjaro off-label or for diabetes typically lose more weight than patients who use Ozempic off-label or for diabetes.

Side effects compared

Both drugs share the GLP-1 class side-effect profile. Rates from SURPASS-2:

Side effect	Tirzepatide 15 mg	Semaglutide 1 mg
Nausea	22.1%	17.9%
Diarrhea	16.5%	11.5%
Vomiting	9.8%	8.3%
Constipation	6.8%	5.7%
Decreased appetite	9.6%	5.7%
Injection-site reaction	3.2%	1.7%

GI rates are modestly higher for tirzepatide at the 15 mg dose. At lower doses, the rates are similar.

Both drugs carry warnings for:

• Acute pancreatitis (rare but documented)
• Gallbladder disease (especially with rapid weight loss)
• Acute kidney injury (usually due to dehydration from vomiting)
• Diabetic retinopathy worsening in patients with pre-existing retinopathy
• Boxed warning for thyroid C-cell tumors based on rodent data

The thyroid risk has not been confirmed in humans. The FDA prescribing information for both drugs lists a contraindication for personal or family history of medullary thyroid carcinoma or MEN-2.

Dosing and titration

The two drugs use different dose ladders. They are not interchangeable on a 1:1 basis.

Mounjaro titration:

• Weeks 1-4: 2.5 mg/week
• Weeks 5-8: 5 mg/week
• Weeks 9+: optional escalation by 2.5 mg every 4 weeks
• Maintenance options: 5, 7.5, 10, 12.5, 15 mg/week

Ozempic titration:

• Weeks 1-4: 0.25 mg/week
• Weeks 5+: 0.5 mg/week (clinical effect dose)
• After 4+ weeks at 0.5 mg: optional 1 mg
• After 4+ weeks at 1 mg: optional 2 mg
• Maintenance options: 0.5, 1, 2 mg/week

Approximate dose equivalency drawn from clinical experience and SURPASS-2 (these are not official):

Mounjaro	Approx Ozempic equivalent
2.5 mg	0.25 mg (entry only)
5 mg	0.5 mg
7.5 mg	1 mg
10 mg	1 to 2 mg
12.5 mg	No semaglutide equivalent
15 mg	No semaglutide equivalent

These conversions are approximate. Individual response varies.

Pen devices and how to inject each

The two pens look and operate differently.

Mounjaro pen. Single-dose, prefilled. Each pen contains exactly one weekly dose of tirzepatide. You attach the pen to your skin, press a button, and hold for about 10 seconds. The needle is hidden. You discard the pen after one use. Each carton contains 4 pens (one month supply).

Ozempic pen. Multi-dose, dial-a-dose. Each pen contains 4 weekly doses. You attach a needle (sold separately or included in some packs), dial the dose, inject, and store the pen in the fridge between doses. The pen is reused for 4 weeks then discarded.

For technique, both pens go subcutaneously into the abdomen, thigh, or upper arm. Both should be rotated between sites to prevent skin reactions. Both can be self-injected without specialized training.

For more on injection technique, see /articles/glp1-hub/who-qualifies-for-glp1-medications.

Cost and insurance coverage

Brand-name pricing in Q1 2026:

Pharmacy	Mounjaro cash price	Ozempic cash price
Walmart	$1,025 to $1,200	$940 to $1,100
CVS	$1,050 to $1,250	$1,000 to $1,150
Costco (members)	$980 to $1,100	$895 to $1,000
Sam's Club (members)	$995 to $1,125	$920 to $1,050

Manufacturer savings cards. Both Eli Lilly and Novo Nordisk offer copay cards for commercially insured patients.

• Mounjaro savings card (Eli Lilly): as low as $25/month for eligible commercial-insurance patients with Mounjaro coverage; up to ~$150 off per fill if Mounjaro is not covered.
• Ozempic savings card (Novo Nordisk): as low as $25/month for eligible commercial-insurance patients with Ozempic coverage on formulary.

Both savings cards exclude Medicare, Medicaid, TRICARE, and VA patients.

Insurance coverage varies more than list price. Many commercial plans place one drug on a preferred tier and the other on a non-preferred tier, which can shift out-of-pocket cost by hundreds per month. Check your plan's formulary and prior-authorization requirements before deciding.

Switching between Mounjaro and Ozempic

Patients sometimes switch because of efficacy, side effects, cost, or supply.

From Ozempic to Mounjaro. Standard practice is to start Mounjaro at 2.5 mg, the labeled starting dose, regardless of prior semaglutide dose. Some providers start at 5 mg if the patient was on Ozempic 1 to 2 mg and tolerating well. Wash-out: take the last semaglutide dose, then start tirzepatide one week later (the next scheduled injection day).

From Mounjaro to Ozempic. Standard practice is to start Ozempic at 0.25 mg. Some providers start at 0.5 mg if the patient was on Mounjaro 5+ mg and tolerating well. Wash-out: same timing.

Stacking the two drugs (taking both at the same time) is not recommended. The receptor activity overlaps and side effects compound.

Which is better for me?

There is no universal "better" answer. The right drug depends on your specific situation.

Mounjaro often makes more sense if:

• You have type 2 diabetes with A1C above 8%
• Weight loss is a primary goal alongside glucose control
• Your insurance covers Mounjaro on a preferred tier
• You prefer single-dose pens (no needle attachment, no fridge storage of mid-pen doses)

Ozempic often makes more sense if:

• You have type 2 diabetes with established cardiovascular disease (Ozempic has the CV risk-reduction indication; Mounjaro does not yet)
• Your insurance covers Ozempic on a preferred tier and Mounjaro is non-formulary
• You experienced intolerable GI side effects on tirzepatide
• You prefer multi-dose pens

For weight-loss-only goals (no diabetes), the relevant comparison is Zepbound vs Wegovy, not Mounjaro vs Ozempic, because the brand-name diabetes versions usually aren't covered by insurance for weight loss.

For more on the weight-loss versions, see /articles/comparison/zepbound-vs-wegovy/.

FAQ

What is the difference between Mounjaro and Ozempic? Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. Ozempic contains semaglutide, which activates only the GLP-1 receptor. Tirzepatide produces larger average weight loss and A1C reduction in head-to-head trials.

Is Mounjaro better than Ozempic for weight loss? On average, yes. SURMOUNT-1 showed 20.9% body-weight loss on tirzepatide 15 mg vs 14.9% on semaglutide 2.4 mg in STEP 1. Note: both molecules are FDA-approved for weight loss under different brand names (Zepbound and Wegovy), not Mounjaro and Ozempic.

Which has worse side effects, Mounjaro or Ozempic? Both share the GLP-1 class profile (nausea, vomiting, diarrhea, constipation). Tirzepatide's GI rates are slightly higher at the 15 mg dose. At lower equivalent doses, rates are similar.

Can I switch from Ozempic to Mounjaro? Yes, with provider guidance. Most patients restart at the standard Mounjaro starting dose of 2.5 mg/week regardless of prior Ozempic dose. The switch typically happens at the next scheduled injection day.

Is Mounjaro a stronger version of Ozempic? No. They are different molecules. Tirzepatide acts on two receptors instead of one. It is not "stronger semaglutide," it is a different drug.

Why does my insurance cover one but not the other? Insurance formularies place drugs on tiers based on negotiated rebates with manufacturers. One PBM may have a deal with Eli Lilly that puts Mounjaro on Tier 2; another may have a deal with Novo Nordisk that puts Ozempic on Tier 2. The decision is financial, not clinical.

Is Mounjaro the same as Zepbound? Yes, both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management. Eli Lilly markets the same drug under two brand names because the FDA requires separate approvals for separate indications.

Is Ozempic the same as Wegovy? Both contain semaglutide. Wegovy goes up to 2.4 mg weekly and is FDA-approved for chronic weight management. Ozempic goes up to 2 mg weekly and is FDA-approved for type 2 diabetes.

Is "Manjaro" the same as Mounjaro? "Manjaro" is a common misspelling. The brand name is Mounjaro, manufactured by Eli Lilly.

Which costs more, Mounjaro or Ozempic? At cash price, Mounjaro typically costs $50 to $150 more per month than Ozempic. With insurance, the cost depends entirely on your plan's formulary placement. Manufacturer savings cards can reduce both to as low as $25/month for eligible patients.

Can I take Mounjaro and Ozempic together? No. Combining two GLP-1 class drugs is not recommended. Side-effect risks compound and there is no proven additional benefit.

Does Mounjaro cause more nausea than Ozempic? Slightly, at the highest doses. In SURPASS-2, tirzepatide 15 mg produced nausea in 22.1% vs 17.9% for semaglutide 1 mg. At lower equivalent doses, rates are similar.

Sources

1. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
4. Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021;9(9):563-574.
5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
6. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist. Mol Metab. 2018;18:3-14.
7. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.
8. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58(18):7370-7380.
9. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. Revised 2024.
10. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. Revised 2024.
11. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Revised 2024.
12. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Revised 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.